Hausstaubmilbe (D. Pteronyssinus) Bencard Allergie (Dermatophagoides Pteronyssinus)

Hausstaubmilbe (D. Pteronyssinus) Bencard Allergie is indicated for specific clinical situations related to house‑dust‑mite allergy.

• Diagnosis of IgE‑mediated allergy to Dermatophagoides pteronyssinus via skin prick testing.
• Allergen‑specific immunotherapy for patients with confirmed house dust mite allergy.
• Adjunct to environmental control measures in comprehensive allergy management.
• Use in specialized allergy clinics under physician supervision.
• Potential inclusion in approved research protocols involving allergen extracts.

Adverse reactions to Hausstaubmilbe (D. Pteronyssinus) Bencard Allergie are generally mild but may include more serious events.

Common

• Local redness at the injection site.
• Swelling or wheal formation.
• Itching or mild pruritus.
• Transient urticaria.
• Mild headache.
• Temporary dizziness.

Serious

• Systemic anaphylaxis.
• Severe bronchospasm or asthma exacerbation.
• Angioedema of the face or throat.
• Hypotension or shock.
• Prolonged urticaria lasting more than 24 hours.
• Serum‑sickness‑like reaction.

Before prescribing Hausstaubmilbe (D. Pteronyssinus) Bencard Allergie, clinicians should consider several precautionary measures.

• Confirm IgE‑mediated sensitivity before initiating immunotherapy.
• Avoid use in patients with uncontrolled asthma.
• Do not use in pregnant or lactating women unless the benefit clearly outweighs potential risk.
• Observe the patient for at least 30 minutes after administration for early signs of systemic reaction.
• Ensure emergency equipment and medications for anaphylaxis are readily available.
• Store the product according to the manufacturer’s temperature and handling instructions.
• Discontinue treatment if a severe adverse reaction occurs.

Certain medications and substances may modify the safety or efficacy of Hausstaubmilbe (D. Pteronyssinus) Bencard Allergie.

Avoid

• Beta‑blockers, which can worsen anaphylactic outcomes.
• ACE inhibitors, due to potential angioedema risk.
• High‑dose systemic corticosteroids that may suppress the immunologic response.
• Antihistamines taken shortly before skin testing, as they can reduce wheal size.
• Immunosuppressants that blunt the intended immunotherapy effect.

Use with caution

• NSAIDs, which may increase the likelihood of systemic reactions.
• IgE‑targeting monoclonal antibodies (e.g., omalizumab).
• Concurrent administration of other allergen extracts.
• Vaccinations given within a short interval of allergen exposure.
• Alcohol consumption, which can potentiate vasodilatory effects.